Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs FLOWTUSS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Relief of productive cough associated with respiratory tract infections,Chronic obstructive pulmonary disease (COPD) exacerbations,Cystic fibrosis (off-label)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is 4–6 hours in adults with normal renal function; prolonged to 8–12 hours in moderate renal impairment (Cr Cl 30–50 m L/min).
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Hepatic metabolism via oxidation and demethylation; primarily excreted renally as metabolites.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Renal elimination of unchanged drug accounts for 60–70%; hepatic metabolism (30–40%) with fecal excretion of metabolites via bile (20–25%) and urine (10–15%).
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
85–90% bound to albumin and alpha-1-acid glycoprotein.
4-6 L/kg; large Vd indicates extensive tissue distribution
1.5–2.0 L/kg; indicates extensive tissue distribution (e.g., lungs, liver).
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral: 75–85% (first-pass metabolism accounts for 15–25% loss).
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
e GFR 30-60 m L/min: 5 mg every 6 hours; e GFR <30 m L/min: 5 mg every 8 hours.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh Class B: 5 mg every 6 hours; Child-Pugh Class C: 2.5 mg every 8 hours.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Children 2-6 years: 2.5 mg orally every 6 hours; 6-12 years: 5 mg orally every 6 hours; >12 years: same as adult.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Initial dose 5 mg every 6 hours; increase cautiously due to increased risk of dizziness and sedation.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
None.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Avoid use with persistent or chronic cough (e.g., smoking, asthma, COPD) unless directed by a physician. Use caution in patients with renal impairment.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Hypersensitivity to guaifenesin or any component; concurrent use with other expectorants.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No specific food interactions. Alcohol may increase CNS depressant effects (dizziness, sedation).
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dextromethorphan is category C; limited human studies show no clear teratogenic risk, but high doses may cause fetal toxicity. Avoid in first trimester; use only if benefit outweighs risk in second and third trimesters.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Guaifenesin and dextromethorphan are excreted in breast milk in low amounts. M/P ratio not established for either. Use with caution; monitor infant for sedation or respiratory depression.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No standard dose adjustment recommended during pregnancy. Use lowest effective dose for shortest duration. Consider pharmacokinetic changes in pregnancy (increased clearance of dextromethorphan may require higher doses for efficacy, but safety limits apply).
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretion, reducing mucus viscosity. Onset of action is 30-60 minutes. Maximum effect requires adequate hydration (8-10 glasses of water daily). Not recommended for chronic cough due to smoking, asthma, or emphysema. Avoid use in patients with persistent cough lasting >1 week or accompanied by fever, rash, or headache. May cause dizziness; caution when driving.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Drink plenty of water to help loosen mucus.,Do not take more than 6 doses in 24 hours.,Discontinue and consult doctor if cough persists >7 days or if fever, rash, or headache develop.,Avoid alcohol; may increase dizziness.,Do not use for chronic cough from smoking or asthma without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs FLOWTUSS, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. FLOWTUSS is a Expectorant that works by FLOWTUSS (guaifenesin) is an expectorant that increases respiratory tract fluid secretions, reducing mucus viscosity and facilitating clearance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and FLOWTUSS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of FLOWTUSS is: 10 mg orally every 4-6 hours as needed for cough; maximum 60 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and FLOWTUSS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. FLOWTUSS is classified as Category C. FLOWTUSS contains guaifenesin and dextromethorphan. Guaifenesin is FDA pregnancy category C; animal studies show fetal abnormalities at high doses, but human data insufficient. Dex. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.